We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hikma Pharmaceuticals Plc | HIK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 59.00 | 3.18% | 1,913.00 | 16:35:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,861.00 | 1,861.00 | 1,920.00 | 1,913.00 | 1,854.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 03/3/2023 06:39 by dudishes Tks W & A for advice.Agree its topping or is it recovering? That is the question? Tipped much earlier by our investor group, but I turned down, at the time. 500 @ 1722 (£8610). Divis, good point, All this type poor, hence why to long AZN rather by buy back in, Pharmies did come the fore, but can they continue to grow, I say yes, but being from that sphere, I'm biased. IMO cheers |
Posted at 18/8/2022 21:47 by lombriz History seems to be repeating itself...Last time, 5 years ago, from memory Barclays issued a £30 target, and the share price promptly finished up at £8. It was a nerve-racking time for investors (including me), before the share price rapidly recovered to £20, largely due to the surprise appointment of an impressive new CEO. The question is, would it rapidly recover this time round? Or would the ending be totally different? |
Posted at 18/8/2022 20:32 by cumnor Punters and IIs are tiring of indebted companies like Hikma which paid divis of 2% for past couple of years, promised the earth and fail to deliver, as recent results show. Meanwhile directors pay themselves huge salaries and bonuses but expect investors to pay dear for the measly dividend. This could have been more generous and the recent falls (not just here) in poor payers share prices reflect a change in attitude to greedy directors.Needs to see a divi of 5% plus before I'd touch this. |
Posted at 12/8/2022 08:02 by buy2sell1 Unbelievable !!!! Skeppy Investor has got another one WRONG !!!Boohoo, Hikma, 4D Pharma Did you get your charts UPSIDE DOWN again, LOSER BOY !!! |
Posted at 14/7/2022 19:22 by buy2sell1 Skeppy Investor - Specialist in LOSING MONEY |
Posted at 07/7/2022 15:28 by montyhedge Other pharma's reaching all time highs, must admit don't know why investors leaving Hikma alone, forecast p.e.10, grown dividends last fifteen years also buybacks. Down 35% on record profits, it's a head scratcher. |
Posted at 27/6/2022 14:29 by montyhedge I don't think so, investors realised, perhaps rather be in a pharma stock forecast p.e 10 and a yield.Rather than a tech stock p.e 50 and jam promised in the future.Crypto is crashing has well. |
Posted at 14/4/2022 10:04 by montyhedge I don't think so no rns. I just think investors think this safe boring 15 years of continuous dividend growth, is not exciting like say Astra or other pharma stocks. |
Posted at 26/2/2022 12:45 by montyhedge What I can see eps 194.7c divide by 1.35 sterling equals 144.22p sterling, divide into shareprice say 2000p that's p.e 13.8.If that's rights wonder why Hikma ignored by investors.Is that what you make it ? |
Posted at 10/2/2022 21:39 by dartboard1 Agree... I think they do a great job ... allocating capital to bolt on acquisitions from cash (better than increasing the dividend like some posters want). Hence why I'm holding HIK for long term. But just offing up what I think plays on the mind of bigger investors, Jordan based founders with a segment of Middle East revenue. Think it's a good growth market personally.. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
